BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22220854)

  • 1. p53 protein expression in chronic lymphocytic leukemia.
    Sellmann L; Carpinteiro A; Nückel H; Scholtysik R; Siemer D; Klein-Hipass L; Kube D; Dürig J; Dührsen U; Stanelle J; Küppers R
    Leuk Lymphoma; 2012 Jul; 53(7):1282-8. PubMed ID: 22220854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
    Fabbri M; Bottoni A; Shimizu M; Spizzo R; Nicoloso MS; Rossi S; Barbarotto E; Cimmino A; Adair B; Wojcik SE; Valeri N; Calore F; Sampath D; Fanini F; Vannini I; Musuraca G; Dell'Aquila M; Alder H; Davuluri RV; Rassenti LZ; Negrini M; Nakamura T; Amadori D; Kay NE; Rai KR; Keating MJ; Kipps TJ; Calin GA; Croce CM
    JAMA; 2011 Jan; 305(1):59-67. PubMed ID: 21205967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.
    Mohr J; Helfrich H; Fuge M; Eldering E; Bühler A; Winkler D; Volden M; Kater AP; Mertens D; Te Raa D; Döhner H; Stilgenbauer S; Zenz T
    Blood; 2011 Feb; 117(5):1622-32. PubMed ID: 21115975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.
    Yu L; Kim HT; Kasar S; Benien P; Du W; Hoang K; Aw A; Tesar B; Improgo R; Fernandes S; Radhakrishnan S; Klitgaard J; Lee C; Getz G; Setlur SR; Brown JR
    Clin Cancer Res; 2017 Feb; 23(3):735-745. PubMed ID: 27503198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
    Dijkstra MK; van Lom K; Tielemans D; Elstrodt F; Langerak AW; van 't Veer MB; Jongen-Lavrencic M
    Leukemia; 2009 Mar; 23(3):625-7. PubMed ID: 18818704
    [No Abstract]   [Full Text] [Related]  

  • 8. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.
    Messmer BT; Nour-Omid TS; Ghia E; Sanchez AB; Kipps TJ
    Leuk Res; 2011 Jul; 35(7):965-7. PubMed ID: 21570119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.
    Lin K; Farahani M; Yang Y; Johnson GG; Oates M; Atherton M; Douglas A; Kalakonda N; Pettitt AR
    Br J Haematol; 2014 Nov; 167(3):346-55. PubMed ID: 25040181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.
    Dickinson JD; Gilmore J; Iqbal J; Sanger W; Lynch JC; Chan J; Bierman PJ; Joshi SS
    Leuk Lymphoma; 2006 Feb; 47(2):231-44. PubMed ID: 16321852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation.
    Diamantopoulos PT; Samara S; Kollia P; Giannakopoulou N; Sofotasiou M; Kalala F; Kodandreopoulou E; Zervakis P; Vassilakopoulos T; Siakantaris M; Mantzourani M; Angelopoulou M; Kyrtshonis MC; Korkolopoulou P; Patsouris E; Viniou NA
    Anticancer Res; 2017 May; 37(5):2387-2391. PubMed ID: 28476805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
    Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
    Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
    Marinelli M; Raponi S; Del Giudice I; De Propris MS; Nanni M; Intoppa S; Milani ML; Mauro FR; Guarini A; Foà R
    Am J Clin Pathol; 2011 Jan; 135(1):173-4. PubMed ID: 21173142
    [No Abstract]   [Full Text] [Related]  

  • 15. Elevated
    Bravo-Navas S; Yáñez L; Romón Í; Pipaón C
    FASEB J; 2019 Sep; 33(9):10477-10489. PubMed ID: 31251079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.
    de Viron E; Michaux L; Put N; Bontemps F; Van Den Neste E
    Leuk Lymphoma; 2012 Aug; 53(8):1445-51. PubMed ID: 22280536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
    Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
    Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
    Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.